Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Phase II, 2-cohort, single arm trial treated with the combination of the following two
agents:
1. Pembrolizumab (MK3475) 200mg, every three weeks, iv
2. Docetaxel 75mg/m2, every three weeks, iv